Many sewage treatment plants use centrifugal pumps to transfer the nitrified mixed liquor from the aeration zone to the anoxic zone for denitrification. These pumps are often referred to as Internal Mixed Liquor Recycle (IMLR) pumps. IMLR may be 200% to 400% the flow rate of influent wastewater (Q.) This is in addition to Return Activated Sludge (RAS) from secondary clarifiers, which may be 100% of Q. (Therefore, the hydraulic capacity of the tanks in such a system should handle at least 400% of annual average design flow (AADF.) At times, the raw or primary effluent wastewater must be carbon-supplemented by the addition of methanol, acetate, or simple food waste (molasses, whey, plant starch) to improve the treatment efficiency. These carbon additions should be accounted for in the design of a treatment facility's organic loading. 
As if pregnancy wasn’t enough of a problem when it comes to women, weight gain and their thyroid, here’s yet another: Women have more thyroid problems than men simply because of breast tissue . Did you know that a woman’s breasts require almost as much iodine as the thyroid ?
So for women, iodine has to do double, or during pregnancy, even triple duty.
There’s even a condition named for this breast tissue iodine deficiency: Fibrocystic Breast Disease . Clinically, a woman with fibrocystic breast disease should be assumed to be thyroid deficient. It has also been reported that women with this specific iodine deficiency disease are also more likely to develop breast cancer than those that don’t.
Since men don’t have these problems, women are unfortunately the ones who are typically more prone to being iodine deficient.
Dr. Bjordal suggests that we graded evidence for acetaminophen too positively. In his letter, Dr. Bjordal describes one trial as evaluating acute low back pain when it actually evaluated chronic low back pain (9). Otherwise, our descriptions of the evidence are similar (Appendix Tables 10 and 11 (2)). We agree that our evidence ratings for acetaminophen were generous given some inconsistency among trials of acute low back pain, and lack of direct evidence and small benefits for chronic low back pain. We re-rated evidence for acetaminophen for acute low back pain fair quality with moderate benefits, and for chronic low back pain fair quality with small benefits (see Correction). Because of acetaminophen's favorable safety profile compared to other pharmacologic therapies, these changes do not change our recommendation to consider it as a first-line option for pharmacologic therapy (1).